Acumen Pharmaceuticals (NASDAQ: ABOS) insider transactions
In the twelve months to 10 November 2026, executives and directors of Acumen Pharmaceuticals reported 48 open-market sales of 305,128 shares ($625,712) and 0 open-market purchases, by 9 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 17 June 2026 | Porter Derrell | Director | Option exercise | +13,040 | $1.07 | 48,540 | Form 4 |
| 17 June 2026 | Porter Derrell | Director | Open-market sale | −13,040 | $2.33 | 35,500 | Form 4 |
| 16 June 2026 | Porter Derrell | Director | Open-market sale | −12,800 | $2.33 | 35,500 | Form 4 |
| 15 June 2026 | Porter Derrell | Director | Option exercise | +6,460 | $1.07 | 54,760 | Form 4 |
| 15 June 2026 | Porter Derrell | Director | Open-market sale | −6,460 | $2.35 | 48,300 | Form 4 |
| 9 June 2026 | Fountain Nathan B | Director | Open-market sale | −6,400 | $2.23 | 48,150 | Form 4 |
| 3 June 2026 | RA Capital Nexus Fund II, L.P. | Director | Grant or award | +35,500 | — | 48,300 | Form 4 |
| 3 June 2026 | Stoppel Laura | Director | Grant or award | +35,500 | — | 48,300 | Form 4 |
| 3 June 2026 | Golumbeski George | Director | Grant or award | +35,500 | — | 35,500 | Form 4 |
| 3 June 2026 | Ives Jeffrey L. | Director | Grant or award | +35,500 | — | 48,300 | Form 4 |
| 3 June 2026 | Porter Derrell | Director | Grant or award | +35,500 | — | 48,300 | Form 4 |
| 3 June 2026 | Stalfort John A III | Director | Grant or award | +35,500 | — | 220,624 | Form 4 |
| 3 June 2026 | Drapkin Kimberlee C | Director | Grant or award | +35,500 | — | 48,300 | Form 4 |
| 3 June 2026 | Fountain Nathan B | Director | Grant or award | +35,500 | — | 54,550 | Form 4 |
| 16 March 2026 | Shah Rajeev M. | Director | Grant or award | +6,060,606 | $3.30 | 19,103,785 | Form 4 |
| 6 March 2026 | Meisner Derek M | Chief Legal Officer & Corp Sec | Option exercise, 10b5-1 plan | +2,090 | $1.85 | 176,089 | Form 4 |
| 6 March 2026 | Meisner Derek M | Chief Legal Officer & Corp Sec | Open-market sale, 10b5-1 plan | −2,090 | $3.26 | 173,999 | Form 4 |
| 27 February 2026 | Meisner Derek M | Chief Legal Officer & Corp Sec | Option exercise, 10b5-1 plan | +9,406 | $1.85 | 183,405 | Form 4 |
| 27 February 2026 | Meisner Derek M | Chief Legal Officer & Corp Sec | Open-market sale, 10b5-1 plan | −9,406 | $3.01 | 173,999 | Form 4 |
| 28 January 2026 | Meisner Derek M | Chief Legal Officer & Corp Sec | Option exercise, 10b5-1 plan | +2,671 | $1.85 | 176,670 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Acumen Pharmaceuticals page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.